Second Meeting of the Subcommittee of the Expert Committee on... Selection and Use of Essential Medicines

Second Meeting of the Subcommittee of the Expert Committee on the
Selection and Use of Essential Medicines
Geneva, 29 September to 3 October 2008
Fluoroquinolones in children
WHO Model List of Essential Medicines for Children lists one fluoroquinolone,
ciprofloxacin (250 mg tablet) and is for the treatment of shigella infections only.
Hence a review was requested on the appropriate use of fluoroquinolones in children
Summary
Fluoroquinolones have important antibacterial and pharmacological properties
favorable for treating several infections in children. There is no definite evidence to
show that they induce sustained injury to developing joints in children. Hence there is
no reason to avoid their use when specific indications exist. There are many
indications in children and shigellosis is just one of them. However, bacterial
resistance to this group is increasing rapidly. Since the probability of adverse events
cannot be excluded totally and the danger of resistance emerging is real, these agents
should not be considered as first line therapy where other options exist.
Currently ciprofloxacin has the most evidence for safety and efficacy in children.
BNF C 2006 recommends ciprofloxacin and cautions that expert advice should be
sought if other fluorquinolones are to be used. It is suitable for use in most conditions
where fluoroquinolones are indicated. However, newer fluoroquinolones are being
evaluated and limited data show these to be effective and safe in children. This needs
to be reviewed when more data becomes available.
Recommendations:
Only ciprofloxacin to be included in the EML C
Shift ciprofloxacin to complementary list
Delete the statement regarding shigella infections
Spectrum
Fluoroquinolones have a very good spectrum of activity [1, 2]. They are active against
several clinically important aerobic Gram negative bacilli like those belonging to
1
enterobacteriaceae (eg E coli) and Pseudomonas aeruginosa. They are also active
against Gram positive cocci like S pneumoniae, S aureus and beta haemolytic
streptococci. H influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae,
Legionella pneumoniae are also susceptible. Anaerobic cover is limited.
Pharmacokinetics
This group of drugs is well absorbed from the gastrointestinal tract and all except
norfloxacin, penetrate well into tissues. Bioavailability ranges from 10-30% for
norfloxacin to 80 -90% for ofloxacin [2]. Elimination is mostly through kidneys,
unchanged. Newer fluoroquinolones have improved properties like longer serum half
life, higher peak levels and bioavailability and extensive tissue penetration [1].
Because of intracellular penetration, they are useful for treating infections due to
Mycobacteria and salmonella [1, 2]. Pharmacokinetic data in children is limited.
Studies show that systemic elimination is more rapid in children and so larger doses
are required [2]. A recent study showed that the newer fluoroquinolone gatifloxacin is
rapidly absorbed in infants and children and allows once a day dosing [3].
Formulations suitable for oral and parenteral use and also for local applications in ear
and eye infections are available.
Because of these reasons, fluoroquinolones are used in adults for a variety of
indications including UTI, respiratory tract infections, skin and soft tissue infections,
bone and joint infections and infections in the ear and eyes [2]. However, their use in
children is limited since animal studies have shown possible joint/cartilage toxicity.
Recent evidence shows that fluoroquinolones are useful for several indications in
children and that arthropathy associated with its use is rare [1, 2, 4]. Although there is
no compelling evidence supporting the occurrence of sustained injury to developing
joints in humans by a fluoroquinolone, the possibility that it occurs infrequently has
not been excluded[4].
Adverse events
Most frequent adverse events are GI related and occur in up to 4% of those treated [1,
2, 5] Prolongation of QT interval and CNS manifestations like head ache, insomnia,
seizures are reported. Transient and reversible eosinopilia, neutropenia, elevated
transaminases can occur. Rashes and photosensitivity are also reported.
Fluoroquiolones with serious adverse events were withdrawn from clinical use [2, 5].
2
In young animals, arthropathy [1, 2] with typical histopathological changes, but
reversible following drug withdrawal and immobilisation, is recorded. Mild to
moderate arthralgia occurred during 31/2030 (1.5%) ciprofloxacin therapy in 1795
children [1]. This is similar to that seen in adults and resolved without interventions.
Another review of 31 reports on use of ciprofloxacin, ofloxacin or nalidixic acid in
more than 7000 children and adolescents concluded that concern regarding
chondrotoxicity is not justified [6]. In a prospective observational study, overall,
adverse events occurred in 18% children with 3.8% musculo skeletal events. This was
significantly higher than in controls (0.4%) [7], but were transient. Drug differences in
cartilage effect exist [1]
Label information on Cipro (Bayer) [5] states that ciprofloxacin (335 children) was
compared with cephalosporin (349 children) in children aged 1-17 yrs with
complicated UTI in a multicentric study involving centers in the US, Canada, South
America, Germany and South Africa. Duration of therapy was for 10-21 days with a
mean of 11 days. An independent Pediatric Safety Committee reviewed all cases.
Findings are summarised in the table.
Findings involving joint and periarticular tissue as reported in Bayer label [5]
Problems subsided spontaneously after stopping therapy. Neurological events like
dizziness, insomina, nervousness and somnolence occurred in 3% of ciprofloxacin
treated group versus 2% in the comparator group. In this trial, overall 41% in the
ciprofloxacin group and 31% in the comparator group reported adverse events. The
most frequent was gastrointestinal. Serious events occurred in 7.5% ciprofloxacin and
5.7% control patients. Drug was discontinued in 3% and 1.4% respectively.
3
Resistance
Inappropriate use of fluoroquinolones in children and adults is associated with rapidly
increasing bacterial resistance to these agents. This aspect is probably of greater
concern than potential adverse events [4, 8].
Uses
The use of fluoroquinolone in a child or adolescent is therefore is restricted to special
circumstances after careful assessment of the risks and benefits for the individual
patient [4]. Indications in children will include treatment of [4]
1. Infections caused by multidrug-resistant pathogens for which there is no safe or
effective alternative or as second line where first line therapy has failed
2. Infections where no other effective oral agent is available and parenteral therapy
is not feasible.
Specific indications in children
BNF C 2006 and Australian Medicines Handbook also list the following indications
FDA Approved [4]
•
Exposure to aerosolized Bacillus anthracis to decrease the incidence or
progression of disease
•
Urinary tract infections caused by multidrug-resistant, Gram-negative bacteria
(FDA licensed for complicated Escherichia coli UTI and pyelonephritis in
patients 1 to 17 years of age).
Increasing resistance to fluoroquinolones among uropathogens is of concern.
Fluoroquinolone resistance has appeared among commensals and uropathogens in
most parts of the world, but prevalence rates vary [9-12].
Others [1, 2, 4]
1. Exacerbation of pulmonary disease in patients with cystic fibrosis (CF): Potential
causative organisms like P. aeruginosa and other bacteria causing respiratory
infections in CF patients are susceptible. Oral ciprofloxacin is shown to be as
efficacious as betalactam and aminoglycoside combination [1]. Use of oral therapy
can avoid hospitalization and can therefore improve quality of life. Longer period of
therapy (3-6 months) was well tolerated [2]. There is most agreement for this
indication [1].
4
2. Typhoid and paratyphoid fevers[1]: Oral ciprofloxacin and ofloxacin bring about
clinical and bacteriological cure in children. However, evidence for superiority over
other drugs is inconclusive. A Cochrane review [13] identified 33 trials of which 3
were exclusively in children. In adults, chloramphenicol was not significantly
different from fluoroquinolones in causing clinical or microbiological failure. In trials
of hospitalized children, fluoroquinolones were not significantly different from
ceftriaxone (60 participants, 1 trial) or cefixime (82 participants, 1 trial). Norfloxacin
had more clinical failures than other fluoroquinolones (417 participants, 5 trials).
Trials comparing different durations of fluoroquinolone treatment showed no
statistically significant differences (693 participants, 8 trials)
3. Gastrointestinal tract infection caused by multidrug-resistant Shigella species[14],
Salmonella species, Vibrio cholerae or Campylobacter jejuni. Incidences of such
strains have increased considerably in recent years. Ciprofloxacin is clinically useful
and safe for GI infections in children [2]. It was used effectively in an out break of
shigellosis [15].
Short courses of therapy are usually sufficient. However, suboptimal dosages can lead
to rapid emergence of resistance or decreasing susceptibility as is being reported from
several countries for Salmonella [16-19], Shigella[20] and Campylobacter [21-23].
Hence careful attention to rational use is necessary, especially for this indication.
4. Chronic suppurative otitis media [2] or malignant otitis externa caused by P.
aeruginosa. Oral or topical applications can be used. A Cochrane review [24]
identified 9 trials (842 analysed participants or ears). Topical quinolones were better
than systemic quinolone and non-quinolone antibiotics at clearing discharge at 1-2
weeks.
Role of fluoroquinolones in acute otitis media (AOM) is limited. However,
Gatifloxacin or Levofloxacin can be useful in treating complicated AOM failing to
respond to initial antibiotic therapy [1] .
5. Gram negative neonatal sepsis/meningitis [2]: Because of the good penetration into
CSF and cerebral tissues and activity on Gram negative bacteria, it can be used for
treating Gram negative meningitis in the new born. It is suggested that it reduces
chance of cerebral abscess formation in the neonates and the immunocompromised
[2]. 116 neonates with microbiologically proven/probable sepsis were treated
successfully with ciprofloxacin. No short term adverse events were observed. No
clinical arthropathy or growth impairment occurred at one year follow up [25]
5
However, since seizures and raised intracranial pressure are listed as adverse events,
close monitoring is required. Some others state that it can be used for neonatal sepsis
but not for meningitis [26]
6. Gram-negative bacterial infections in immuno-compromised hosts in which oral
therapy is desired or resistance to alternative agents is present
7. As second line in bacterial septicemia or meningitis in infants and children in
whom therapy with other appropriate antimicrobial agents has failed .
8. Chronic or acute osteomyelitis or osteochondritis [2]: Fluoroquinolones reach high
concentrations in the bones and joints and have action against common aetiological
agents. It is shown to be clinically effective for those infections caused by P.
aeruginosa and so is recommended for this infection.
9. Children with serious allergy to alternative agents and severe infections with
fluoroquinolones-susceptible pathogens
10. Mycobacterial infections
Among the various fluoroquinolones, Ciprofloxacin is most potent against
pseudomonas and most data on safety and efficacy in children are on this drug. It is
effective for all indications listed above. Gatifloxacin, levofloxacin, gemifloxacin,
moxifloxacin are more recent introductions with better activity against S pneumoniae
and other Gram positive bacteria. Limited data shows that gatifloxacin is safe and
effective in children and has convenient dosing schedule [2]. However, more evidence
is required for their clinical utility and superiority over ciprofloxacin in terms of
efficacy and safety for the various indications in children. It is also better to prevent
wide spread use of newer fluoroquinolones to minimize development of resistance.
1.
Leibovitz, E., The use of fluoroquinolones in children. Curr Opin Pediatr,
2006. 18(1): p. 64-70.
2.
Velissariou, I.M., The use of fluoroquinolones in children: recent advances.
Expert Rev Anti Infect Ther, 2006. 4(5): p. 853-60.
3.
Capparelli, E.V., et al., Pharmacokinetics of gatifloxacin in infants and
children. Antimicrob Agents Chemother, 2005. 49(3): p. 1106-12.
4.
Committee on Infectious Diseases.The use of systemic fluoroquinolones.
Pediatrics, 2006. 118(3): p. 1287-92.
5.
Label, Cipro, Bayer Health Care, Bayer Pharmaceuticals corporation. 2007.
6.
Burkhardt, J.E., J.N. Walterspiel, and U.B. Schaad, Quinolone arthropathy in
animals versus children. Clin Infect Dis, 1997. 25(5): p. 1196-204.
6
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
Chalumeau, M., et al., Fluoroquinolone safety in pediatric patients: a
prospective, multicenter, comparative cohort study in France. Pediatrics,
2003. 111(6 Pt 1): p. e714-9.
Murray, T.S. and R.S. Baltimore, Pediatric uses of fluoroquinolone
antibiotics. Pediatr Ann, 2007. 36(6): p. 336-42.
Sharifian, M., et al., Microbial sensitivity pattern in urinary tract infections in
children: a single center experience of 1,177 urine cultures. Jpn J Infect Dis,
2006. 59(6): p. 380-2.
Qin, X., et al., Ciprofloxacin-resistant gram-negative bacilli in the fecal
microflora of children. Antimicrob Agents Chemother, 2006. 50(10): p. 33259.
Gaspari, R.J., et al., Multidrug resistance in pediatric urinary tract infections.
Microb Drug Resist, 2006. 12(2): p. 126-9.
Yuksel, S., et al., Antibiotic resistance of urinary tract pathogens and
evaluation of empirical treatment in Turkish children with urinary tract
infections. Int J Antimicrob Agents, 2006. 28(5): p. 413-6.
Thaver, D., et al., Fluoroquinolones for treating typhoid and paratyphoid fever
(enteric fever). Cochrane Database Syst Rev, 2005(2): p. CD004530.
WHO, Guidelines for the control of shigellosis including epidemics due to
Shigella dysenteriae type 1. 2005.
Guerin, P.J., et al., Case management of a multidrug-resistant Shigella
dysenteriae serotype 1 outbreak in a crisis context in Sierra Leone, 19992000. Trans R Soc Trop Med Hyg, 2004. 98(11): p. 635-43.
Capoor, M.R., et al., In vitro activity of azithromycin, newer quinolones and
cephalosporins in ciprofloxacin-resistant Salmonella causing enteric fever. J
Med Microbiol, 2007. 56(Pt 11): p. 1490-4.
Maskey, A.P., et al., Emerging trends in enteric fever in Nepal: 9124 cases
confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg, 2008.
102(1): p. 91-5.
Whichard, J.M., et al., Human Salmonella and concurrent decreased
susceptibility to quinolones and extended-spectrum cephalosporins. Emerg
Infect Dis, 2007. 13(11): p. 1681-8.
Joshi, S. and S.K. Amarnath, Fluoroquinolone resistance in Salmonella typhi
and S. paratyphi A in Bangalore, India. Trans R Soc Trop Med Hyg, 2007.
101(3): p. 308-10.
Rahman, M., et al., Increasing spectrum in antimicrobial resistance of
Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone
and decreased susceptibility to ciprofloxacin. J Health Popul Nutr, 2007.
25(2): p. 158-67.
van Hees, B.C., et al., Regional and seasonal differences in incidence and
antibiotic resistance of Campylobacter from a nationwide surveillance study
in The Netherlands: an overview of 2000-2004. Clin Microbiol Infect, 2007.
13(3): p. 305-10.
Serichantalergs, O., et al., Emerging fluoroquinolone and macrolide resistance
of Campylobacter jejuni and Campylobacter coli isolates and their serotypes
in Thai children from 1991 to 2000. Epidemiol Infect, 2007. 135(8): p. 1299306.
Sack, D.A., et al., Antimicrobial resistance in shigellosis, cholera and
campylobacteriosis, in Background document for the WHO global strategy for
containment of antimicrobial resistance. 2001.
7
24.
25.
26.
Macfadyen, C.A., J.M. Acuin, and C. Gamble, Systemic antibiotics versus
topical treatments for chronically discharging ears with underlying eardrum
perforations. Cochrane Database Syst Rev, 2006(1): p. CD005608.
Drossou-Agakidou, V., et al., Use of ciprofloxacin in neonatal sepsis: lack of
adverse effects up to one year. Pediatr Infect Dis J, 2004. 23(4): p. 346-9.
Sankar, M.J., et al., Sepsis in the newborn, AIIMS-NICU protocols. Division of
Neonatology, Department of Pediatrics, All India Institute of Medical
Sceinces, New Delhi, India, 2008.
8